Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12

Simona Sica, Luca Laurenti, Francesco Autore, Idanna Innocenti, Francesco Corrente, Marino Gentile, Serena Molica, Alessandra Ferretti, Celeste Vitale, Maria Chiara Tisi, Robin Foa, Paolo Strati, Livio Trentin, Agostino Cortelezzi, Carlo Visco, Marta Coscia, Antonio Cuneo, Alessandro Gozzetti, Francesca Romana Mauro, Anna Maria FrustaciMassimo Gentile, Fortunato Morabito, Stefano Molica, Paolo Falcucci, Giovanni D’Arena, Roberta Murru, Donatella Vincelli, Dimitar G. Efremov, Antonietta Ferretti, Gian Matteo Rigolin, Candida Vitale, Gianluigi Reda, Andrea Visentin, Robin Foà, Alessandra Ferrajoli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

Chronic Lymphocytic Leukemia (CLL) patients with +12 have been reported to have specific clinical and biologic features. We performed an analysis of the association between demographic; clinical; laboratory; biologic features and outcome in CLL patients with +12 to identify parameters predictive of disease progression; time to treatment; and survival. The study included 487 treatment-naive CLL patients with +12 from 15 academic centers; diagnosed between January 2000 and July 2016; and 816 treatment-naïve patients with absence of Fluorescence In Situ Hybridization (FISH) abnormalities. A cohort of 250 patients with +12 CLL followed at a single US institution was used for external validation. In patients with +12; parameters associated with worse prognosis in the multivariate model were high Lactate DeHydrogenase (LDH) and β-2- microglobulin and unmutated immunoglobulin heavy-chain variable region gene (IGHV). CLL patients with +12 and high LDH levels showed a shorter Progression-Free-Survival (PFS) (30 months vs. 65 months; p < 0.001), Treatment-Free-Survival (TFS) (33 months vs. 69 months; p < 0.001), Overall Survival (OS) (131 months vs. 181 months; p < 0.001) and greater CLL-related mortality (29% vs. 11% at 10 years; p < 0.001) when compared with +12 CLL patients with normal LDH levels. The same differences were observed in the validation cohort. These data suggest that serum LDH levels can predict PFS; TFS; OS and CLL-specific survival in CLL patients with +12.
Lingua originaleEnglish
pagine (da-a)896-N/A
RivistaCancers
Volume11
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • CLL
  • LDH
  • Prognosis
  • Trisomy 12

Fingerprint

Entra nei temi di ricerca di 'Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12'. Insieme formano una fingerprint unica.

Cita questo